Valuation: Haleon plc

Capitalization 29.29B 39.62B 33.8B 30.96B 54.28B 3,786B 54.58B 369B 143B 1,799B 148B 145B 6,253B P/E ratio 2026 *
17.1x
P/E ratio 2027 * 15.4x
Enterprise value 36.16B 48.92B 41.73B 38.23B 67.02B 4,675B 67.38B 455B 177B 2,221B 183B 180B 7,720B EV / Sales 2026 *
3.17x
EV / Sales 2027 * 2.99x
Free-Float
99.43%
Yield 2026 *
2.41%
Yield 2027 * 2.68%
1 day-1.55%
1 week-1.26%
Current month-3.00%
1 month-9.42%
3 months-18.89%
6 months-12.77%
Current year-12.01%
1 week 325
Extreme 325
338.8
1 month 325
Extreme 325
361.3
Current year 325
Extreme 325
416.1
1 year 274.4
Extreme 274.4
419.5
3 years 274.4
Extreme 274.4
419.5
5 years 241.17
Extreme 241.1735
419.5
10 years 241.17
Extreme 241.1735
419.5
Manager TitleAgeSince
Chief Executive Officer 59 21/07/2021
Director of Finance/CFO 56 31/10/2024
Chief Tech/Sci/R&D Officer 63 31/07/2025
Director TitleAgeSince
Director/Board Member 59 22/05/2022
Chairman 71 31/12/2025
Director/Board Member 59 17/07/2022
Change 5d. change 1-year change 3-years change Capi.($)
-1.55%-1.26%-18.37%-3.85% 40.18B
+2.61%+2.72%+34.43%+133.81% 883B
+2.75%+2.16%+49.49%+43.31% 540B
+0.31%+1.16%+9.70%+41.69% 367B
-0.94%-1.00%+20.39%+10.73% 328B
+0.13%+3.27%+34.01%+14.62% 288B
+0.78%+2.87%+27.40%+26.23% 283B
+0.96%+0.27%+41.05%-3.15% 278B
+0.91%+4.65%-32.22%-49.10% 206B
+0.05%+2.08%+22.45%+44.43% 181B
Average -0.09%+0.99%+18.83%+25.87% 339.39B
Weighted average by Cap. -0.02%+0.60%+27.40%+49.76%

Financials

2026 *2027 *
Net sales 11.39B 15.41B 13.14B 12.04B 21.11B 1,472B 21.22B 143B 55.64B 700B 57.73B 56.54B 2,432B 11.88B 16.07B 13.71B 12.56B 22.02B 1,536B 22.14B 150B 58.03B 730B 60.21B 58.97B 2,536B
Net income 1.73B 2.34B 2B 1.83B 3.21B 224B 3.23B 21.83B 8.47B 106B 8.78B 8.6B 370B 1.89B 2.56B 2.18B 2B 3.51B 245B 3.52B 23.83B 9.24B 116B 9.59B 9.39B 404B
Net Debt 6.87B 9.3B 7.93B 7.27B 12.74B 889B 12.81B 86.57B 33.58B 422B 34.84B 34.12B 1,467B 6.28B 8.49B 7.25B 6.64B 11.64B 812B 11.7B 79.09B 30.67B 386B 31.83B 31.17B 1,340B
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (29.5%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (22.8%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (17.7%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - vitamins, minerals and food supplements (15.1%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. - respiratory medicines (14.9%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.2%), North America (36%), and Asia/Pacific (22.8%).
Employees
24,535
Date Price Change Volume
13/05/26 329.80 p -1.55% 21,958,660
12/05/26 335.00 p +2.42% 26,298,880
11/05/26 327.10 p -1.24% 26,589,230
08/05/26 331.20 p -1.16% 39,711,090
07/05/26 335.10 p +0.12% 24,705,550
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.298GBP
Average target price
4.175GBP
Spread / Average Target
+26.58%

Quarterly revenue - Rate of surprise